The disease stems from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Because different variants of this gene dictate the severity of symptoms, physicians now tailor management strategies to the specific mutation identified. Routine screening has become a standard, with prospective parents opting for blood tests to determine carrier status, while newborns in the United States undergo mandatory heel-prick testing shortly after delivery.

While no cure exists, the therapeutic landscape has shifted significantly. CFTR modulators—oral medications designed to improve protein function—have transformed long-term outcomes for both children and adults. Effective management now relies on a coordinated team of pulmonologists, dietitians, respiratory therapists, and other specialists, reflecting a move toward holistic, multidisciplinary care. These combined efforts have markedly improved life expectancy compared to assessments from just a decade ago.